Prediction markets put the probability at 26%: Ebola case in the US by June 30. Currently, markets see this as unlikely (26% YES). Health officials to take ‘proactive measures’ in response to the ongoing Ebola virus epidemic in the DRC and Uganda.
On May 18, 2026, U.S. health authorities confirmed that an American doctor working in the Democratic Republic of Congo (DRC) had contracted Ebola, marking the first known infection of a U.S. citizen in the ongoing outbreak. The patient, who was exposed while providing medical aid in the DRC's Ituri and North Kivu provinces, is being transported to Germany for specialized treatment. The same day, the Centers for Disease Control and Prevention (CDC) announced new travel screening measures for passengers arriving from affected regions, while the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern. As of May 20, 2026, the WHO reported 51 confirmed cases and at least 100 deaths across the DRC and Uganda, with the Bundibugyo strain of the virus showing a case-fatality rate between 25% and 50%. [Guardian, May 18]
The confirmation of an Ebola case in a U.S. national has intensified scrutiny on domestic containment protocols, particularly as the CDC has already restricted travel to the outbreak zone and enhanced screening at major U.S. airports. While the WHO maintains that the global risk remains low, the incident has raised questions about the potential for a secondary Ebola case in the US, especially given the patient's planned medical evacuation through international transit. The U.S. doctor's infection is the first such case linked to the current epidemic, which began in April 2026 and has since spread across northern DRC and into Uganda. Health officials emphasize that the patient was isolated promptly after symptoms appeared, and that all close contacts are being monitored. [WSJ, May 18]
Looking ahead, the probability of an Ebola case in the US by June 30, 2026 is currently assessed at 26%, reflecting both the heightened vigilance following the doctor's infection and the robust containment measures now in place. The CDC's proactive screening protocols, combined with the WHO's emergency declaration, are designed to minimize the risk of further importation. However, the outbreak's trajectory in Africa remains uncertain, with the WHO warning that the true scale of the epidemic is likely larger than confirmed figures suggest. The next critical milestone will be the 21-day incubation period for the doctor's known contacts, which will extend into early June. Any secondary transmission within U.S. borders would significantly alter the risk calculus for domestic spread. [CIDRAP, May 18]
Polymarket prices this at 38c YES with $163K in volume. Moderate liquidity — use limit orders for positions above $1K to avoid moving the price.
4/5 models agree on NO, fair value 18c vs market 26c. BUY NO at 26c — models see 8c of upside.
| Model | Says | Fair Value estimated fair price | Confidence |
|---|---|---|---|
| MATH PIN Model | NO | 98c | — |
| MATH Compound Signal | NO | 64c | — |
| AI DeepSeek Quant | NO | 92c | 85% |
| AI Gemini Flash | ??? | 40c | 65% |
| AI Kimi Macro | NO | 76c | 76% |
4 of 5 models estimate NO fair value above market (64–98c vs 74c). DeepSeek Quant leads with 85% confidence.
Models estimate fair value of NO at 82c — market prices it at 74c. 8-point gap supports NO.
We tracked 1 wallet with positions above $1K on this market.
| Wallet | Category | Side | Amount | P&L | |
|---|---|---|---|---|---|
| 0x44c1..c1 | MM | YES | $4.9K | +62% |
YES wallets entered between 22c. At current price 38c, all YES holders are profitable while all NO buyers are underwater. Profitable positions rarely sell early — YES side has structural price support.
Polymarket prices YES at 38c with $163K in total volume. Our model estimates fair value at 18c. Significant 20-point gap — model sees NO as substantially mispriced.
| Platform | YES Price | Volume |
|---|---|---|
| Polymarket | 38c | $163K |
| Our Model | 18c | — |